Leo Pharma is acquiring Bayer’s dermatology unit with 450 employees

Leo Pharma is acquiring Bayer’s dermatology unit with 450 employees
Shots:
  • The agreement includes drug for treatment of acne, fungal skin infections and rosacea, and a range of topical steroids summing up an annual turnover of ≥280 Mn Euros in 2017
  •  Leo will have global product rights including sales, marketing in 14 countries except Afghanistan and Pakistan and a manufacturing site in Italy
  • Acquisition closure will be during 2018 in the US and during H2’19 for RoW
Click here to read full press release/ article | Ref: Bayer | Image: Forbes